"Higher for Longer" Interest Rates: Clinical-stage biopharmaceutical companies like Cue Biopharma are highly dependent on external funding for extensive R&D and clinical trials. Elevated and sustained high interest rates increase the cost of borrowing, making it more expensive to secure capital, and can diminish investor appetite for speculative, pre-revenue growth stocks, thereby impacting company valuations and ability to finance operations.

Inflation Drives Up Operational Costs: With US inflation at 3.3%, Cue Biopharma faces increased operational expenditures. This affects the costs of essential research materials, laboratory supplies, and the salaries of highly specialized scientific and clinical personnel, potentially accelerating the company's cash burn rate and necessitating more capital raises.

General Market Sentiment for Biotech/High-Growth Stocks: In a market characterized by economic uncertainty and tightening monetary policies, investors often shift capital away from riskier, development-stage biotech companies towards more stable, profitable assets. This risk aversion can lead to lower valuations for companies like Cue Biopharma and create challenges in securing sufficient funding for ongoing and future drug development programs.